Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Validating A Better ALS Biomarker With Coya's Fred Grossman
Fred discusses $COYA's 1H2024 plans for a IND application and the 2H2024 P2 trial.
https://www.clinicalleader.com/doc/validating-a-better-als-biomarker-with-coya-s-fred-grossman-0001
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-the-3rd-Annual-ALS-Drug-Development-Summit/default.aspx
And in the world of ALS.
Amylyx Pharmaceuticals said it would voluntarily remove its drug for amyotrophic lateral sclerosis from the market, a rare move that comes less than a month after a clinical trial showed its once-promising treatment for the fatal disease doesn’t work.
https://www.washingtonpost.com/business/2024/04/04/amylyx-als-drug/
Investing in the fight against ALS. Hosted by Schwab Network.
https://schwabnetwork.com/video/investing-in-the-fight-against-als
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033159/coya-20240319.htm
Neuroimmune Pharmacology Conference Powerpoint
https://s201.q4cdn.com/307844724/files/doc_news/2024/NeuroimmunePharmacology3-12-2024-4.pdf
Dr. Stan Appel will be presenting during a 30-minute segment at the The 28th Society of Neuroimmune Pharmacology Conference.
March 10-13, 2024 The Francis Marion Hotel, Charleston
https://s-nip.org/documents/2024/SNIP_2024_Schedule.pdf
Empowering Patient Story and Coya’s Fight Against Neurodegenerative Diseases
Coya’s VP of Operations and Patient Advocacy, Daniel Barvin, had the opportunity to shed light on the world of his empowering patient story and Coya’s fight against neurodegenerative diseases in Houston for the Reel Abilities, UP Abilities event.
21 Feb: COYA letter to stockholders.
About ALS:
ALS is a progressive disease, meaning the symptoms get worse over time. The functional status of ALS patients declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease.
COYA results:
Patients' disease progression was measured using the ALSFRS-R scale. The mean scores after initiation of treatment were not statistically different compared to the score at baseline, suggesting significant amelioration in the progression of the disease over the 48-week treatment period.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93265319/coya-therapeutics-licenses-intellectual-property-r
SEC Form 4's
$COYA announced small option grants (5000 shr @ $7.41) for 3 BOD members. I expect more announcements to come.
$COYA current shares in issue: 10M
A Private placement announced DEC 5 2023 added 4.4M shares + 319K warrants.
Prospectus announced today will allow those shares to trade. The 319K warrants may also be exercised.
Currently most shares are held tightly.
I'm not much of a predictor. And most of the shares are tightly held.
But the company does have my respect and a good outlook long term.
Where do you see the PPS heading by year end
Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in patients with ALS upon acceptance of the IND
Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population
https://medicalxpress.com/news/2023-12-scientists-year-old-mystery-once-elusive-source.html
2023, $COYA has secured a private placement agreement plus a partnership agreement with $RDY. These two deals will provide non-dilutive financing thru 2026.
T-Cells are a focus of COYA research. Understanding the language is helpful.
CAR-T cells are Chimeric Antigen Receptors. (T-Cells)
Tregs are Regulatory T-Cells.
T-Cells have great potential.
‘It’s all gone’: CAR-T therapy forces autoimmune diseases into remission
$COYA $26.5M private placement.
A very newsy 8-K
$COYA Therapeutics has posted several YT videos.
https://www.youtube.com/@coyatherapeutics7911/videos
Brief Hometown Houston interview with $COYA CEO Howard Berman.
https://cw39.com/news/health/new-study-at-houston-methodist-hospital-for-alzheimers-disease/
$COYA's web site does not provide a clear picture of on-going clinical trials. And the studies at clinicaltrials.net don't tie back to the company or COYA-301. Dear COYA, why not?
COYA 301 Phase 1 Trial NCT05821153
COYA 301 Phase 2 Trial NCT06096090
It's obvious $COYA is not in the hands of traders.
COYA trading volume:
Friday recorded 60 trades for a total volume of 3.7K
Shares in issue 10.56m
Coya News and events page:
https://ir.coyatherapeutics.com/news/default.aspx
Coya will be presenting at at the 18th International Conference on Alzheimer’s & Parkinson’s Disease in Lisbon.
Coya Announces Acceptance of Oral Presentation
This completed P1 trial also tested COYA 301 (not by name) Low-Dose IL-2 administered SubQ.
NCT05821153
Coya is associated with this P2 clinical trial:
NCT06096090
I'm not sure why COYA is not directly tagged on the page.
The drug being tested in Low-Dose IL-2 administered SubQ. <<< THAT IS COYA 301.
COYA 301 is a new formulation of an existing drug: Proleukin® (aldesleukin).
Proleukin is designed to be administered by intravenous infusion.
COYA 301 is designed to be administered by subcutaneous injection.
Subcutaneous injection is intended for slow sustained absorption.
COYA and other biotechs are focusing on Exosomes as a delivery mechanism.
Exosomes explained:
Welcome to the COYA stock message board. 1st test posting.
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
38
|
Created
|
11/17/23
|
Type
|
Free
|
Moderators FooBarAndGrill |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |